Daiki Taguchi1, Masahiro Inoue1, Koji Fukuda1, Taichi Yoshida1, Kazuhiro Shimazu1, Kazuma Fujita2, Hiroyuki Okuyama3, Nobuhisa Matsuhashi4, Akihito Tsuji3, Kazuhiro Yoshida4, Masatomo Miura2, Hiroyuki Shibata5. 1. Department of Clinical Oncology, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita, Japan. 2. Department of Pharmacy, Akita University Hospital, Hondo 1-1-1, Akita, Japan. 3. Department of Clinical Oncology, Kagawa University, Ikedo 1750-1, Miki-cho, Kida-gun, Kagawa, Japan. 4. Department of Surgical Oncology, Gifu University Graduate School of Medicine, Yanagito 1-1, Gifu, Gifu, Japan. 5. Department of Clinical Oncology, Akita University Graduate School of Medicine, Hondo 1-1-1, Akita, Japan. hiroyuki@med.akita-u.ac.jp.
Abstract
BACKGROUND: Regorafenib is a multiple tyrosine kinase inhibitor, and the use of this drug is approved for the treatment of cancers that are resistant to chemotherapy, which include advanced colorectal cancer, gastrointestinal stromal tumor, and hepatocellular carcinoma. However, the drug causes adverse events, including skin toxicities that require dose modification in approximately 75% of cases. At present, the blood concentration of regorafenib is not assessed in clinical settings; thus, we recently developed a method that can assess the blood concentration of the drug using high-performance liquid chromatography. METHODS: We measured the trough blood concentrations (Ctrough) of regorafenib and its metabolites (M2 and M5) in 14 and 4 patients with advanced colorectal cancer and gastrointestinal stromal tumor, respectively, using high-performance liquid chromatography. Then, the correlation between the Ctrough and therapeutic outcomes of regorafenib was analyzed. RESULTS: In patients who were receiving regorafenib 40-160 mg/day, the Ctrough values of regorafenib, M2, and M5 were 318-9467, 34-3594, and 38-3796 ng/mL, respectively. The difference in the values was significant. Although the specific factors influencing this difference were not elucidated, the Ctrough of regorafenib was extremely lower in some patients, even though the drug was administered at a standard dose, which may explain the lower response rate. Moreover, the Ctrough value of M5 was significantly correlated to the incidence of skin toxicities, which is the most frequent cause of dose modification. CONCLUSIONS: The use of regorafenib may not be suitable in patients with a low Ctrough value. To prevent skin toxicities, the Ctrough value of M5 should be monitored.
BACKGROUND:Regorafenib is a multiple tyrosine kinase inhibitor, and the use of this drug is approved for the treatment of cancers that are resistant to chemotherapy, which include advanced colorectal cancer, gastrointestinal stromal tumor, and hepatocellular carcinoma. However, the drug causes adverse events, including skin toxicities that require dose modification in approximately 75% of cases. At present, the blood concentration of regorafenib is not assessed in clinical settings; thus, we recently developed a method that can assess the blood concentration of the drug using high-performance liquid chromatography. METHODS: We measured the trough blood concentrations (Ctrough) of regorafenib and its metabolites (M2 and M5) in 14 and 4 patients with advanced colorectal cancer and gastrointestinal stromal tumor, respectively, using high-performance liquid chromatography. Then, the correlation between the Ctrough and therapeutic outcomes of regorafenib was analyzed. RESULTS: In patients who were receiving regorafenib 40-160 mg/day, the Ctrough values of regorafenib, M2, and M5 were 318-9467, 34-3594, and 38-3796 ng/mL, respectively. The difference in the values was significant. Although the specific factors influencing this difference were not elucidated, the Ctrough of regorafenib was extremely lower in some patients, even though the drug was administered at a standard dose, which may explain the lower response rate. Moreover, the Ctrough value of M5 was significantly correlated to the incidence of skin toxicities, which is the most frequent cause of dose modification. CONCLUSIONS: The use of regorafenib may not be suitable in patients with a low Ctrough value. To prevent skin toxicities, the Ctrough value of M5 should be monitored.
Authors: Y Ando; H Saka; M Ando; T Sawa; K Muro; H Ueoka; A Yokoyama; S Saitoh; K Shimokata; Y Hasegawa Journal: Cancer Res Date: 2000-12-15 Impact factor: 12.701
Authors: I Cascorbi; T Gerloff; A Johne; C Meisel; S Hoffmeyer; M Schwab; E Schaeffeler; M Eichelbaum; U Brinkmann; I Roots Journal: Clin Pharmacol Ther Date: 2001-03 Impact factor: 6.875
Authors: Suzanne George; Qian Wang; Michael C Heinrich; Christopher L Corless; Meijun Zhu; James E Butrynski; Jeffrey A Morgan; Andrew J Wagner; Edwin Choy; William D Tap; Jeffrey T Yap; Annick D Van den Abbeele; Judith B Manola; Sarah M Solomon; Jonathan A Fletcher; Margaret von Mehren; George D Demetri Journal: J Clin Oncol Date: 2012-05-21 Impact factor: 44.544
Authors: Bert Vogelstein; Nickolas Papadopoulos; Victor E Velculescu; Shibin Zhou; Luis A Diaz; Kenneth W Kinzler Journal: Science Date: 2013-03-29 Impact factor: 47.728
Authors: Anne Sacré; Nicolas Lanthier; Hélène Dano; Selda Aydin; Daniela Leggenhager; Achim Weber; Anne-France Dekairelle; Astrid De Cuyper; Jean-Luc Gala; Yves Humblet; Christine Sempoux; Marc Van den Eynde Journal: Liver Int Date: 2016-09-06 Impact factor: 5.828
Authors: Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent Journal: Lancet Date: 2012-11-22 Impact factor: 79.321
Authors: D Strumberg; M E Scheulen; B Schultheis; H Richly; A Frost; M Büchert; O Christensen; M Jeffers; R Heinig; O Boix; K Mross Journal: Br J Cancer Date: 2012-05-08 Impact factor: 7.640
Authors: Xuejiao Ren; Qingning Zhang; Wenyan Guo; Lan Wang; Tao Wu; Wei Zhang; Ming Liu; Dezhi Kong Journal: Front Pharmacol Date: 2022-08-22 Impact factor: 5.988